Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin–niacin combination therapy

European Journal of Cardiovascular Prevention & Rehabilitation

Volumn 9, Issue 6, 2002, Pages 339-347

  Duvall, W Lane ^a   Blazing, Michael A ^a   Saxena, Shilpa ^a   Guyton, John R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

high density lipoproteins; hydroxymethylglutaryl CoA reductase inhibitors; low density lipoproteins; nicotinic acid; total HDL cholesterol ratio

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; STATIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; REDUCTION; RETROSPECTIVE STUDY;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FLUSHING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; NIACIN; PRAVASTATIN; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 0036924019     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/174182670200900607     Document Type: Article

References (51)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707–714.
2. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: A prospective case–control study. Lancet 1977; i: 965–968.
3. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325: 373–381.
4. Illingworth DR, Bacon S. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs. Arteriosclerosis 1989; 9(suppl 1):I-121–I-134.
5. Henkin Y, Oberman A, Hurst DC, Segrest JP. Niacin revisited: Clinical observations on an important but underutilized drug. Am J Med 1991; 91: 239–246.
6. Tsalamandris C, Panagiotopoulos S, Sinha A, Cooper ME, Jerums G. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidemia in diabetic and non-diabetic patients. J Cardiovasc Risk 1994; 1: 231–239.
7. Brown BG, Bardsley J, Poulin D, Hillger LA, Dowdy A, Maher VM, et al Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol #38;#60; 100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 1997; 80: 111–115.
8. Gardner SF, Marx MA, White LM, Granberry MC, Skelton DR, Fonseca VA. Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. Ann Pharmacother 1997; 31: 677–682.
9. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM. Effectiveness of once nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998; 82: 737–743.
10. Guyton JR, Capuzzi DM. Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol 1999; 82: 82U–84U.
11. Wolfe ML, Vartanian SF, Ross JL, Bansavich LL, Mohler ER III, Meagher E, et al Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 2001; 87: 476–479.
12. Jacobson TA, Chin MM, Fromell GJ, Jokubaitis LA, Amorosa LF. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol 1994; 74: 149–154.
13. O'Keefe JH Jr, Harris WS, Nelson J, Windsor SL. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol 1995; 76: 480–484.
14. Gardner SF, Schneider EF, Granberry MC, Carter IR. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy 1996; 16: 419–423.
15. Davignon J, Roederer G, Montigny M, Hayden MR, Tan MH, Connelly PW, et al Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994; 73: 339–345.
16. Vacek JL, Dittmeier G, Chiarelli T, White J, Bell HH. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol 1995; 76: 182–184.
17. Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and ‘normal’ cholesterol levels. A randomized, placebo-controlled trial. Ann Intern Med 1996; 125: 529–540.
18. Garg R, Elam MB, Crouse JR III, Davis KB, Kennedy JW, Egan D, et al Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. Am Heart J 2000; 140: 792–803.
19. Adult Treatment Panel III. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 2001; 285: 2486–2496.
20. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
21. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–1307.
22. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009.
23. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. J Am Med Assoc 1998; 279: 1615–1622.
24. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357.
25. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc 1984; 251: 351–374.
26. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410–418.
27. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al Relation of gemfibrozil treatment and lipid levels with major coronary events: Va-HIT: A randomized controlled trial. J Am Med Assoc 2001; 285: 1585–1591.
28. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583–1592.
29. Merck & Company. Product information for Mevacor (lovastatin). In: Physician's Desk Reference. Montvale, New Jersey: Medical Economics Company Inc. 2001. pp. 1968–1971.
30. National Cholesterol Education Program. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). J Am Med Assoc 1993; 269: 3015–3023.
31. Friedewald W, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
32. Guyton JR. Treatment of type III hyperlipoproteinemia. Am Heart J 1999; 138: 17–18.
33. Adult Treatment Panel II. National Cholesterol Education Program econd report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Bethesda: National Institutes of Health; 1993. pp. I-9–I-10.
34. Knopp RH, Alagona P, Davidson M, Goldberg AC, Kafonek SD, Kashyap M, et al Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998; 47: 1097–1104.
35. Guyton JR, Blazing MA, Hagar J, Kashyap ML, Knopp RH, McKenney JM, et al Extended-release niacin versus gemfibrozil for treatment of low levels of high density lipoprotein cholesterol. Arch Intern Med 2000; 160: 1177–1184.
36. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096–1107.
37. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al Discontinuation of antihyperlipidemic drugs–do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125–1131.
38. Morgan JM, Capuzzi DM, Guyton JR, Centor RM, Goldberg R, Robbins DC, et al Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: A placebo-controlled trial. J Cardiovasc Pharmacol Therapeut 1996; 1: 195–202.
39. Hill MD, Bilbao JM. Case of the month: February 1999–54 year old man with severe muscle weakness. Brain Pathol 1999; 9: 607–608.
40. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988; 109: 597–598.
41. Cooke HM. Lovastatin- and niacin-induced rhabdomyolysis. Hospital Pharmacy 1994; 29: 33–34.
42. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. J Am Med Assoc 1994; 271: 672–677.
43. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992; 92: 77–81.
44. Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, et al Efficacy and safety of an extended-release niacin (Niaspan); a long-term study. Am J Cardiol 1999; 82: 74U–81U.
45. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486–2497.
46. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RC. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. J Am Med Assoc 1990; 264: 3007–3012.
47. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet 2001; 357: 577–581.
48. The Post Coronary Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153–162.
49. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999; 341: 70–76.
50. Heart Protection Society Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002; 360: 7–22.
51. Guyton JR. The role of lipoproteins in atherogenesis. In: Longenecker JB, Kritchevsky D, Drezner MC, (editors) Nutrition and Biotechnology in Heart Disease and Cancer. New York: Plenum; 1995. pp. 29–38.